RuscogeninCAS# 472-11-7 |
- (25RS)-Ruscogenin
Catalog No.:BCN7805
CAS No.:874485-32-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 472-11-7 | SDF | Download SDF |
PubChem ID | 441893 | Appearance | White powder |
Formula | C27H42O4 | M.Wt | 430.63 |
Type of Compound | Steroids | Storage | Desiccate at -20°C |
Solubility | DMSO : 125 mg/mL (290.28 mM; Need ultrasonic) | ||
SMILES | CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(C(CC(C6)O)O)C)C)C)OC1 | ||
Standard InChIKey | QMQIQBOGXYYATH-IDABPMKMSA-N | ||
Standard InChI | InChI=1S/C27H42O4/c1-15-7-10-27(30-14-15)16(2)24-22(31-27)13-21-19-6-5-17-11-18(28)12-23(29)26(17,4)20(19)8-9-25(21,24)3/h5,15-16,18-24,28-29H,6-14H2,1-4H3/t15-,16+,18-,19-,20+,21+,22+,23-,24+,25+,26+,27-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Ruscogenin exerts significant anti-inflammatory and anti-thrombotic activities.Ruscogenin significantly attenuates LPS-induced acute lung injury (ALI )via inhibiting expressions of TF and iNOS and NF-κB p65 activation, it inhibits activation of neutrophil through cPLA 2 , PAK, Akt, MAPKs, cAMP, and PKA signaling pathways. |
Targets | PGE | TNF-α | NF-kB | p65 | NO | NOS | COX | ERK | JNK | Akt | p38MAPK | PKA | cAMP | IL Receptor |
In vivo | Possible mechanism of the anti-inflammatory activity of ruscogenin: role of intercellular adhesion molecule-1 and nuclear factor-kappaB.[Pubmed: 18946195]J Pharmacol Sci. 2008 Oct;108(2):198-205.Ruscogenin (RUS), first isolated from Ruscus aculeatus, also a major steroidal sapogenin of traditional Chinese herb Radix Ophiopogon japonicus, has been found to exert significant anti-inflammatory and anti-thrombotic activities. Ruscogenin ameliorates experimental nonalcoholic steatohepatitis via suppressing lipogenesis and inflammatory pathway.[Pubmed: 25136608]Biomed Res Int. 2014;2014:652680.The aim of the study was to investigate the protective effects of Ruscogenin, a major steroid sapogenin in Ophiopogon japonicus, on experimental models of nonalcoholic steatohepatitis. |
Kinase Assay | Ruscogenin suppresses mouse neutrophil activation: Involvement of protein kinase A pathway.[Reference: WebLink]Ruscogenin reduces cerebral ischemic injury via NF-κB-mediated inflammatory pathway in the mouse model of experimental stroke.[Pubmed: 23911884]Eur J Pharmacol. 2013 Aug 15;714(1-3):303-11.Transient cerebral ischemia initiates a complex series of inflammatory events, which has been associated with an increase in behavioral deficits and secondary brain damage. Ruscogenin is a major steroid sapogenin in the traditional Chinese herb Ophiopogon japonicus that have multiple bioactivities. Recent studies have demonstrated that Ruscogenin is involved in down-regulation of intercellular adhesion molecule-1 (ICAM-1) and nuclear factor-κB (NF-κB) activation in anti-inflammatory pathways. J. Steroid Biochem., 2015, 154:85-93.Ruscogenin, a natural steroidal sapogenin, presents in both food and medicinal plants. It has been found to exert significant anti-inflammatory activities.
|
Cell Research | Ruscogenin inhibits lipopolysaccharide-induced acute lung injury in mice: involvement of tissue factor, inducible NO synthase and nuclear factor (NF)-κB.[Pubmed: 22079591 ]Int Immunopharmacol. 2012 Jan;12(1):88-93.Acute lung injury is still a significant clinical problem with a high mortality rate and there are few effective therapies in clinic. |
Ruscogenin Dilution Calculator
Ruscogenin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3222 mL | 11.6109 mL | 23.2218 mL | 46.4436 mL | 58.0545 mL |
5 mM | 0.4644 mL | 2.3222 mL | 4.6444 mL | 9.2887 mL | 11.6109 mL |
10 mM | 0.2322 mL | 1.1611 mL | 2.3222 mL | 4.6444 mL | 5.8054 mL |
50 mM | 0.0464 mL | 0.2322 mL | 0.4644 mL | 0.9289 mL | 1.1611 mL |
100 mM | 0.0232 mL | 0.1161 mL | 0.2322 mL | 0.4644 mL | 0.5805 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- MK-0752
Catalog No.:BCC2090
CAS No.:471905-41-6
- Boc-D-Ser(Bzl)-OH
Catalog No.:BCC3448
CAS No.:47173-80-8
- (E)-Aldosecologanin
Catalog No.:BCN4631
CAS No.:471271-55-3
- Bufotaline
Catalog No.:BCN5368
CAS No.:471-95-4
- Stachydrine
Catalog No.:BCN8384
CAS No.:471-87-4
- (-)-Steviol
Catalog No.:BCN8358
CAS No.:471-80-7
- Dipterocarpol
Catalog No.:BCN5523
CAS No.:471-69-2
- alpha-Boswellic acid
Catalog No.:BCN5522
CAS No.:471-66-9
- Isocolumbin
Catalog No.:BCN5361
CAS No.:471-54-5
- Glycyrrhetinic acid
Catalog No.:BCN5942
CAS No.:471-53-4
- 8-Amino-7-oxononanoic acid
Catalog No.:BCN1778
CAS No.:4707-58-8
- Atraric acid
Catalog No.:BCN5521
CAS No.:4707-47-5
- Betulinic acid
Catalog No.:BCN5524
CAS No.:472-15-1
- Telocinobufagin
Catalog No.:BCN2359
CAS No.:472-26-4
- Butyrospermol
Catalog No.:BCN3340
CAS No.:472-28-6
- Masticadienolic acid
Catalog No.:BCN5525
CAS No.:472-30-0
- Astaxanthin
Catalog No.:BCN2248
CAS No.:472-61-7
- H-Ser(Bzl)-OH
Catalog No.:BCC3031
CAS No.:4726-96-9
- Kartogenin
Catalog No.:BCC6211
CAS No.:4727-31-5
- 1-Benzyl-4-hydroxypiperidine
Catalog No.:BCC8459
CAS No.:4727-72-4
- 8(14),15-Isopimaradien-3-ol
Catalog No.:BCN5526
CAS No.:4728-30-7
- SB 366791
Catalog No.:BCC7128
CAS No.:472981-92-3
- alpha-Cyperone
Catalog No.:BCN1193
CAS No.:473-08-5
- beta-Eudesmol
Catalog No.:BCN6294
CAS No.:473-15-4
Possible mechanism of the anti-inflammatory activity of ruscogenin: role of intercellular adhesion molecule-1 and nuclear factor-kappaB.[Pubmed:18946195]
J Pharmacol Sci. 2008 Oct;108(2):198-205.
Ruscogenin (RUS), first isolated from Ruscus aculeatus, also a major steroidal sapogenin of traditional Chinese herb Radix Ophiopogon japonicus, has been found to exert significant anti-inflammatory and anti-thrombotic activities. Our previous studies suggested that Ruscogenin remarkably inhibited adhesion of leukocytes to a human umbilical vein endothelial cell line (ECV304) injured by tumor necrosis factor-alpha (TNF-alpha) in a concentration-dependent manner. Yet the underlying mechanisms remain unclear. In this study, the in vivo effects of Ruscogenin on leukocyte migration and celiac prostaglandin E(2) (PGE(2)) level induced by zymosan A were studied in mice. Furthermore, the effects of Ruscogenin on TNF-alpha-induced intercellular adhesion molecule-1 (ICAM-1) expression and nuclear factor-kappaB (NF-kappaB) activation were also investigated under consideration of their key roles in leukocyte recruitment. The results showed that Ruscogenin significantly suppressed zymosan A-evoked peritoneal total leukocyte migration in mice in a dose-dependent manner, while it had no obvious effect on PGE(2) content in peritoneal exudant. Ruscogenin also inhibited TNF-alpha-induced over expression of ICAM-1 both at the mRNA and protein levels and suppressed NF-kappaB activation considerably by decreasing NF-kappaB p65 translocation and DNA binding activity. These findings provide some new insights that may explain the possible molecular mechanism of Ruscogenin and Radix Ophiopogon japonicus for the inhibition of endothelial responses to cytokines during inflammatory and vascular disorders.
Ruscogenin reduces cerebral ischemic injury via NF-kappaB-mediated inflammatory pathway in the mouse model of experimental stroke.[Pubmed:23911884]
Eur J Pharmacol. 2013 Aug 15;714(1-3):303-11.
Transient cerebral ischemia initiates a complex series of inflammatory events, which has been associated with an increase in behavioral deficits and secondary brain damage. Ruscogenin is a major steroid sapogenin in the traditional Chinese herb Ophiopogon japonicus that have multiple bioactivities. Recent studies have demonstrated that Ruscogenin is involved in down-regulation of intercellular adhesion molecule-1 (ICAM-1) and nuclear factor-kappaB (NF-kappaB) activation in anti-inflammatory pathways. We hypothesized that Ruscogenin protects against brain ischemia by inhibiting NF-kappaB-mediated inflammatory pathway. To test this hypothesis, adult male mice (C57BL/6 strain) were pretreated with Ruscogenin and then subjected to transient middle cerebral artery occlusion (MCAO)/reperfusion. After 1 h MCAO and 24 h reperfusion, neurological deficit, infarct sizes, and brain water content were measured. Ruscogenin markedly decreased the infarct size, improved neurological deficits and reduced brain water content after MCAO. The activation of NF-kappaB Signaling pathway was observed after 1h of ischemia and 1h of reperfusion, and Ruscogenin significantly inhibited NF-kappaB p65 expression, phosphorylation and translocation from cytosol to nucleus at this time point in a dose-dependent manner. NF-kappaB DNA binding activity, and the expression of NF-kappaB target genes, including ICAM-1, inducible nitric oxide synthase (iNOS), cyclooxygenase (COX-2), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), were also suppressed by Ruscogenin pretreatment after 1 h MCAO and 24 h reperfusion. The results indicated that Ruscogenin protected the brain against ischemic damage caused by MCAO, and this effect may be through downregulation of NF-kappaB-mediated inflammatory responses.
Ruscogenin ameliorates experimental nonalcoholic steatohepatitis via suppressing lipogenesis and inflammatory pathway.[Pubmed:25136608]
Biomed Res Int. 2014;2014:652680.
The aim of the study was to investigate the protective effects of Ruscogenin, a major steroid sapogenin in Ophiopogon japonicus, on experimental models of nonalcoholic steatohepatitis. HepG2 cells were exposed to 300 mumol/l palmitic acid (PA) for 24 h with the preincubation of Ruscogenin for another 24 h. Ruscogenin (10.0 mumol/l) had inhibitory effects on PA-induced triglyceride accumulation and inflammatory markers in HepG2 cells. Male golden hamsters were randomly divided into five groups fed a normal diet, a high-fat diet (HFD), or a HFD supplemented with Ruscogenin (0.3, 1.0, or 3.0 mg/kg/day) by gavage once daily for 8 weeks. Ruscogenin alleviated dyslipidemia, liver steatosis, and necroinflammation and reversed plasma markers of metabolic syndrome in HFD-fed hamsters. Hepatic mRNA levels involved in fatty acid oxidation were increased in Ruscogenin-treated HFD-fed hamsters. Conversely, Ruscogenin decreased expression of genes involved in hepatic lipogenesis. Gene expression of inflammatory cytokines, chemoattractive mediator, nuclear transcription factor-(NF-) kappaB, and alpha-smooth muscle actin were increased in the HFD group, which were attenuated by Ruscogenin. Ruscogenin may attenuate HFD-induced steatohepatitis through downregulation of NF-kappaB-mediated inflammatory responses, reducing hepatic lipogenic gene expression, and upregulating proteins in beta-oxidation pathway.
Ruscogenin inhibits lipopolysaccharide-induced acute lung injury in mice: involvement of tissue factor, inducible NO synthase and nuclear factor (NF)-kappaB.[Pubmed:22079591]
Int Immunopharmacol. 2012 Jan;12(1):88-93.
Acute lung injury is still a significant clinical problem with a high mortality rate and there are few effective therapies in clinic. Here, we studied the inhibitory effect of Ruscogenin, an anti-inflammatory and anti-thrombotic natural product, on lipopolysaccharide (LPS)-induced acute lung injury in mice basing on our previous studies. The results showed that a single oral administration of Ruscogenin significantly decreased lung wet to dry weight (W/D) ratio at doses of 0.3, 1.0 and 3.0 mg/kg 1 h prior to LPS challenge (30 mg/kg, intravenous injection). Histopathological changes such as pulmonary edema, coagulation and infiltration of inflammatory cells were also attenuated by Ruscogenin. In addition, Ruscogenin markedly decreased LPS-induced myeloperoxidase (MPO) activity and nitrate/nitrite content, and also downregulated expression of tissue factor (TF), inducible NO synthase (iNOS) and nuclear factor (NF)-kappaB p-p65 (Ser 536) in the lung tissue at three doses. Furthermore, Ruscogenin reduced plasma TF procoagulant activity and nitrate/nitrite content in LPS-induced ALI mice. These findings confirmed that Ruscogenin significantly attenuate LPS-induced acute lung injury via inhibiting expressions of TF and iNOS and NF-kappaB p65 activation, indicating it as a potential therapeutic agent for ALI or sepsis.